Kalin Katherine Bach
Known title: DirectorCIK: 0001832671
Kalin Katherine Bach's purchase track record
Kalin Katherine Bach has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/19/2025 | SLS | $101K | +149.3% | +490.1% | +11.9% |
| 5/22/2025 | SLS | $36K | 0.0% | -17.1% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SLS | ▲ Buy | Grant | 50,000 | $0 | 1/7/2026 | View on chart |
| SLS | ▲ Buy | Open Market | 63,400 | $101K | 11/19/2025 | View on chart |
| SLS | ▲ Buy | Open Market | 20,000 | $36K | 5/22/2025 | View on chart |
| SLS | ▲ Buy | Grant | 12,500 | $0 | 1/10/2025 | View on chart |
| SLS | ▲ Buy | Grant | 6,000 | $0 | 1/22/2024 | View on chart |
| SLS | ▲ Buy | Grant | 2,500 | $0 | 2/2/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SLS Stock Fluctuates Amid M&A Speculation and New AML Study
SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.
SLS Stock Fluctuates Amid M&A Speculation and New AML Study. SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.